Heart scans of inflammation and rhythm problems after catheter aortic valve replacement
Looks at inflammation on PET scans and rhythm problems in people with aortic stenosis.
Key facts
- Who runs it
- Centre Hospitalier Regional Et Universitaire De Brest
- Where
- France1 site in 1 countryChoose a country to see its sites
- Registry title
- Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography on exploratory cohort
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 17 Jun 2024
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional
- Record updated
- 7 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe narrowing of the aortic heart valve (aortic stenosis) who will get a new valve placed through a blood vessel in the groin (TAVI). It studies whether inflammation seen on an 18F-FDG PET-CT scan is linked to heart rhythm conduction problems after the procedure.
- Age
- Over 18 years.
- Sex
- All sexes can join.
- Disease stage
- Tight aortic stenosis on a resting heart ultrasound: valve area ≤ 1cm2 (or indexed area ≤ 0.6 cm2/m2), OR maximum velocity ≥ 4 m/s, OR mean gradient ≥ 40 mmHg. Patients must have symptoms: breathlessness at NYHA stage 2 or more, or an abnormal stress test. Patients without symptoms can join if LVEF is < 50%. Blood vessels must allow valve placement through the groin artery.
- Earlier treatment
- People who already have a pacemaker or triple-chamber defibrillator before TAVI cannot join. People with an earlier TAVI valve or mechanical valve, in any position, cannot join.
Main reasons for not taking part
- Pacemaker or triple-chamber defibrillator before TAVI, or an earlier TAVI or mechanical valve
- Aortic valve with one or two leaflets (uni or bicuspid)
- Severe weak heart pumping (LVEF < 30%) or other major valve disease
- Life expectancy < 12 months
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients over 18 years of age
- Patient with tight aortic stenosis defined by aortic valve area ≤ 1cm2 (or indexed aortic valve area ≤ 0.6 cm2/m2 body surface area), OR maximum transvalvular velocity ≥ 4 m/s OR mean transvalvular gradient ≥ 40 mmHg, assessed by transthoracic echocardiography (TTE) performed in a patient at rest
- Symptomatic patient with: dyspnea ≥ stage 2 according to New York Heart Association (NYHA) classification OR pathological stress test with onset of symptoms on exertion, drop in blood pressure or rhythm disturbance on exertion OR Asymptomatic with Left Ventricular Ejection Fraction (LVEF) < 50%
- Patient with vascular anatomy compatible with percutaneous femoral valve implantation
- Patient affiliated to or benefiting from a health insurance scheme
- Patient has provided free, informed and written consent
Who cannot take part
- Patients with pacemakers or triple-chamber defibrillators prior to TAVI (Transcatheter Aortic Valve Implantation) implantation
- Patients with other significant valvulopathies: aortic insufficiency ≥ grade 3, mitral insufficiency ≥ grade 3 or tight mitral stenosis
- Patients with severe left ventricular dysfunction (LVEF < 30%)
- Patient deprived of liberty by judicial or administrative decision, under guardianship or trusteeship
- Patient with life expectancy < 12 months
- Patients with a uni or bicuspid aortic valve
- Patient with iliofemoral vascular anatomy preventing safe passage of valve
- Patient with pre-existing TAVI bioprosthesis or mechanical prosthesis, in any position
- Inability or refusal to give consent
- Pregnant or breast-feeding woman
- Patients under court protection or family guardianship
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To study the association between the occurrence of conduction disorders after percutaneous aortic valve and the degree of inflammation of intramyocardial conduction pathways assessed by 18F-FDG PET-CT, based on observation of subjects in an exploratory cohort.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography on exploratory cohort
- Plain-language title
- Heart scans of inflammation and rhythm problems after catheter aortic valve replacementGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 7 November 2025